drugset / Trial / NCT01239108
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.
Timeline
- Start
- 2010-10
- Primary completion
- 2012-04
- Completion
- 2012-04
Outcome
Outcome not reported
Stopped: “The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe to continue clinical development of this molecule.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGI-1776 | Small molecule | 350 mg | Oral |
| Subject | SGI-1776 | Small molecule | 1600 mg | Oral |